410 related articles for article (PubMed ID: 34835116)
21. SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection.
Khateeb D; Gabrieli T; Sofer B; Hattar A; Cordela S; Chaouat A; Spivak I; Lejbkowicz I; Almog R; Mandelboim M; Bar-On Y
PLoS Pathog; 2022 Jan; 18(1):e1010242. PubMed ID: 35020754
[TBL] [Abstract][Full Text] [Related]
22. Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests.
De Marco Verissimo C; O'Brien C; López Corrales J; Dorey A; Cwiklinski K; Lalor R; Doyle JM; Field S; Masterson C; Ribes Martinez E; Hughes G; Bergin C; Walshe K; McNicholas B; Laffey JG; Dalton JP; Kerr C; Doyle S
Epidemiol Infect; 2021 Jun; 149():e140. PubMed ID: 34099081
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline.
Bolotin S; Tran V; Osman S; Brown KA; Buchan SA; Joh E; Deeks SL; Allen VG
J Infect Dis; 2021 Apr; 223(8):1334-1338. PubMed ID: 33400794
[TBL] [Abstract][Full Text] [Related]
24. Genomic characterization of the dominating Beta, V2 variant carrying vaccinated (Oxford-AstraZeneca) and nonvaccinated COVID-19 patient samples in Bangladesh: A metagenomics and whole-genome approach.
Rahaman MM; Sarkar MMH; Rahman MS; Islam MR; Islam I; Saha O; Akter S; Banu TA; Jahan I; Habib MA; Goswami B; Bari L; Malek MA; Khan MS
J Med Virol; 2022 Apr; 94(4):1670-1688. PubMed ID: 34939673
[TBL] [Abstract][Full Text] [Related]
25. Clinical Presentation of COVID-19 and Antibody Responses in Bangladeshi Patients Infected with the Delta or Omicron Variants of SARS-CoV-2.
Ghosh AK; Landt O; Yeasmin M; Sharif M; Ratul RH; Molla MA; Nafisa T; Mosaddeque MB; Hosen N; Bulbul MRH; Mamunur R; Islam A; Shakil SS; Kaiser M; Amin MR; Lytton SD
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423054
[TBL] [Abstract][Full Text] [Related]
26. Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
BMC Immunol; 2021 Oct; 22(1):70. PubMed ID: 34666683
[TBL] [Abstract][Full Text] [Related]
27. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants.
Weigang S; Fuchs J; Zimmer G; Schnepf D; Kern L; Beer J; Luxenburger H; Ankerhold J; Falcone V; Kemming J; Hofmann M; Thimme R; Neumann-Haefelin C; Ulferts S; Grosse R; Hornuss D; Tanriver Y; Rieg S; Wagner D; Huzly D; Schwemmle M; Panning M; Kochs G
Nat Commun; 2021 Nov; 12(1):6405. PubMed ID: 34737266
[TBL] [Abstract][Full Text] [Related]
28. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
29. Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies.
Edouard S; Jaafar R; Orain N; Parola P; Colson P; La Scola B; Fournier PE; Raoult D; Drancourt M
Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1309-1317. PubMed ID: 33660134
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
[TBL] [Abstract][Full Text] [Related]
31. Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study.
Schaffner A; Risch L; Weber M; Thiel S; Jüngert K; Pichler M; Wohlwend N; Lung T; Ritzler M; Hillmann D; Copeland S; Renz H; Paprotny M; Risch M
Clin Chem Lab Med; 2020 Nov; 59(2):e49-e51. PubMed ID: 33554502
[No Abstract] [Full Text] [Related]
32. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
[TBL] [Abstract][Full Text] [Related]
33. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
[TBL] [Abstract][Full Text] [Related]
34. The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients.
Smits VAJ; Hernández-Carralero E; Paz-Cabrera MC; Cabrera E; Hernández-Reyes Y; Hernández-Fernaud JR; Gillespie DA; Salido E; Hernández-Porto M; Freire R
Biochem Biophys Res Commun; 2021 Mar; 543():45-49. PubMed ID: 33515911
[TBL] [Abstract][Full Text] [Related]
35. Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
Mveang Nzoghe A; Leboueny M; Kuissi Kamgaing E; Maloupazoa Siawaya AC; Bongho EC; Mvoundza Ndjindji O; Padzys GS; Ndeboko B; Ategbo S; Djoba Siawaya JF
BMC Res Notes; 2021 Apr; 14(1):152. PubMed ID: 33879229
[TBL] [Abstract][Full Text] [Related]
36. A rapid and low-cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-based RT-qPCR.
Abdel Sater F; Younes M; Nassar H; Nguewa P; Hamze K
Mol Biol Rep; 2021 Nov; 48(11):7243-7249. PubMed ID: 34613565
[TBL] [Abstract][Full Text] [Related]
37. Detection of SARS-CoV-2 VOC-Omicron using commercial sample-to-answer real-time RT-PCR platforms and melting curve-based SNP assays.
Sit BHM; Po KHL; Cheung YY; Tsang AKL; Leung PKL; Zheng J; Lam AYT; Lam ETK; Ng KHL; Chan RCW
J Clin Virol Plus; 2022 Aug; 2(3):100091. PubMed ID: 35761832
[TBL] [Abstract][Full Text] [Related]
38. Emergence of SARS-CoV-2 variant of interest B.1.525 (Eta) in Bangladesh.
Goswami B; Sarkar MMH; Akter S; Banu TA; Jahan I; Hossain MS; Uddin MM; Nafisa T; Molla MMA; Yeasmin M; Osman E; Uzzaman MS; Mahmud ASM; Habib A; Khan S
Biologicals; 2023 Nov; 84():101714. PubMed ID: 37804694
[TBL] [Abstract][Full Text] [Related]
39. Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?
Nasrallah GK
EBioMedicine; 2022 Feb; 76():103831. PubMed ID: 35081490
[No Abstract] [Full Text] [Related]
40. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y
Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
